On the evening of the 26th, Pfizer officially announced a strategic cooperation with China Resources Pharmaceutical Commercial on four varieties. The commercial operation of Pfizer's four tumor treatment drugs AROMASIN®, IBRANCE®, Pharmorubicin RD®, and XALKORI® in China will be responsible for China Resources Pharmaceutical Commercial.

Pfizer stated in an external announcement that Jean-Christophe Pointeau, President of Pfizer China, and Han Yuewei, Deputy General Manager of China Resources Group, attended and witnessed the signing of the contract between the two parties.

Exemestane and epirubicin have entered multiple alliance procurement catalogs, and palbociclib and crizotinib are national negotiation varieties, and the prices are far lower than when they were first listed. It is also worth noting that looking at the drugs in the tenth batch of national procurement catalogs released a few days ago, palbociclib has been listed, and another price reduction is inevitable.

The cooperation will officially start on December 1. Pfizer said that in the next few days, Pfizer's leadership team will work with the leadership team of China Resources Pharmaceutical Commercial to communicate with employees affected by this cooperation and share more details about this change to ensure a smooth transition.

https://mp.weixin.qq.com/